


PRODUCT INFORMATION



Ruxolitinib

Item No. 11609

CAS Registry No.: 941678-49-5
Formal Name: β R-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile
Synonym: INCB 018424
MF: C₁₇H₁₈N₆
FW: 306.4
Purity: \geq 98%
Stability: \geq 2 years at -20°C
Supplied as: A crystalline solid
UV/Vis.: λ_{max} : 216, 224, 253, 309 nm



Laboratory Procedures

For long term storage, we suggest that ruxolitinib be stored as supplied at -20°C. It should be stable for at least two years.

Ruxolitinib is supplied as a crystalline solid. A stock solution may be made by dissolving the ruxolitinib in the solvent of choice. Ruxolitinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of ruxolitinib in ethanol is approximately 13 mg/ml and approximately 5 mg/ml in DMSO and DMF.

Ruxolitinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ruxolitinib should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Ruxolitinib has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Janus-associated kinases (JAKs) are cytoplasmic tyrosine kinases that are required for activating the signaling of certain cytokines and growth factor receptors.^{1,2} A JAK2 gene fusion mutation, JAK2^{V617F}, that causes unchecked activation of various growth factors and cytokines, has been linked to myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.³ Ruxolitinib is a potent ATP mimetic that inhibits both JAK1 and JAK2 with IC₅₀ values of 2.7 and 4.5 nM, respectively and is relatively less selective for JAK3 (IC₅₀ = 322 nM).³ It can block interleukin-6 (IL-6) signaling (IC₅₀ = 281 nM) and proliferation of JAK2^{V617F+} Ba/F3 cells (IC₅₀ = 127 nM).⁴ In primary cultures, ruxolitinib preferentially suppresses erythroid progenitor colony formation from JAK2^{V617F+} polycythemia vera patients (IC₅₀ = 67 nM) versus healthy donors (IC₅₀ > 400 nM).⁴ In a mouse model of JAK2^{V617F+} MPN, 90 mg/kg ruxolitinib reduced splenomegaly, decreased circulating levels of IL-6 and TNF- α , eliminated neoplastic cells, and prolonged survival of the treated animals.⁴

References

1. Leonard, W.J. and O'Shea, J.J. *Annu. Rev. Immunol.* **16**, 293-322 (1998).
2. Yamaoka, K., Saharinen, P., Pesu, M., et al. *Genome Biol.* **5(12)**, 1-6 (2004).
3. Verstovsek, S. *Hematology Am. Soc. Hematol. Educ. Program* **2009(1)**, 636-642 (2009).
4. Quintás-Cardama, A., Vaddi, K., Liu, P., et al. *Blood* **115(15)**, 3109-3117 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/04/2015

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM